The EIF4EBP1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the EIF4EBP1 gene is disrupted in the AGS gastric adenocarcinoma cell line. This mixed population contains diverse knockout alleles, avoiding clonal artifacts and providing a robust loss-of-function model for pooled functional analyses. The model is designed for studies requiring population-level knockout rather than single-cell clones, and it enables systematic interrogation of EIF4EBP1 function without the constraints of monoclonal expansion.
AGS cells are an epithelial model derived from a diffuse gastric adenocarcinoma, widely employed in gastric cancer research. They retain key oncogenic signaling features, including constitutive activation of PI3K/Akt/mTOR and MAPK/ERK pathways, which are directly relevant to EIF4EBP1 regulation. The cell line’s genetic background makes it a suitable host for investigating mTOR-driven translation dysregulation, drug sensitivity, and metabolic adaptation in a disease-relevant context.
EIF4EBP1 encodes 4E-BP1, a translational repressor that binds eIF4E to inhibit cap-dependent translation initiation. mTORC1, activated by insulin, growth factors (EGF, IGF-1), or amino acids, phosphorylates 4E-BP1, causing its dissociation from eIF4E and permitting eIF4F assembly. Key downstream targets derepressed upon phosphorylation include cyclin D1, c-Myc, and VEGF. Under stress, AMPK or hypoxia maintains 4E-BP1 hypophosphorylated, sustaining translational arrest. 4E-BP1 interacts directly with eIF4E and the mTORC1 component Raptor, integrating signals from Akt and MAPK/ERK to control the translation of growth-promoting mRNAs.
Gastric adenocarcinomas frequently exhibit mTOR pathway hyperactivation, leading to constitutive 4E-BP1 phosphorylation and unchecked protein synthesis. The AGS cell line endogenously displays such mTOR activity, making it a representative model to study the impact of EIF4EBP1 loss on malignant phenotypes. Deletion of 4E-BP1 removes a critical translational checkpoint, allowing dissection of its role in proliferation, apoptosis, drug resistance, and metabolic reprogramming. This knockout model thus provides a platform to evaluate therapeutic strategies targeting translation control in gastric cancer.
The EIF4EBP1 Knockout AGS Polyclonal Cells support investigation of mTOR signaling, translation control, and drug resistance in gastric cancer. Typical assays include phospho-4E-BP1 western blot, cap-binding assays, polysome profiling, co-immunoprecipitation of eIF4E, mTOR kinase activity, proliferation assays, and cell cycle flow cytometry. The polyclonal format facilitates pooled genetic screens. For technical inquiries, contact Ascent Research.
